Graft-Versus-Host Disease (GVHD) Market (COVID-19 Impact Analysis) – Size, Share, Trends …

Graft-Versus-Host Disease (GVHD) Market

With this Graft-Versus-Host Disease (GVHD) Market research report, insights and realities of the Healthcare industry can be focused which helps keep the business on the right track. The report contains remarkable market data, present market trends, product consumption, environment, technological innovation, future prospects, upcoming technologies and the technical progress in the related industry. Graft-Versus-Host Disease (GVHD) Market report analyzes the market status, growth rate, future trends, market drivers, market restraints, key opportunities, challenges, market risks, entry barriers, sales channels, distributors  Porter’s Five Forces Analysis. This market analysis report categorizes the market by companies, geographical region, type, component, application and end-use industry.

Get FREE Sample PDF (including COVID19 Impact Analysis) of Market Report @

Market Analysis: Global Graft-Versus-Host Disease (GVHD) Market 

Global Graft-Versus-Host Disease (GVHD) Market is expected to rise gradually to an estimated value of USD 656.00 million by 2026, registering a CAGR of 6.05% in the forecast period of 2019-2026 with the annual sales of USD 410.00 million in the year 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Key Market Competitors: Global Graft-Versus-Host Disease (GVHD) Market 

Few of the major competitors currently working in the graft-versus-host disease market are Sanofi (France), Novartis AG (Switzerland), Neovii Biotech GmbH (Germany), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Soligenix, Inc. (US), Mesoblast Ltd. (Australia), Johnson & Johnson Services, Inc. (US), Mallinckrodft (US), ElsaLys Biotech SA (France), Incyte Corporation (US), Kiadis Pharma (Netherlands) and few among others.

Get Full TOC, Tables and Figures of Market Report @

Market Definition: Global Graft-Versus-Host Disease (GVHD) Market 

Graft-versus-host disease is a rare disease that affects people whose immune system is deficient or suppressed and who recently received a bone marrow transplant or a blood transfusion. It can be identified on the basis of severity i.e. acute, chronic and prophylactic. The symptoms mainly include skin problems, diarrhea, nausea, abdominal pain and liver failure.

According to the Center for International Blood and Marrow Transplant Research, there are about 25,000 allogeneic stem cell transplants are performed per year globally, affects half or more of recipients, almost more than half of these cases could have been avoided with the availability of proper medical equipment and devices for healthcare procedures. This significant number is expected to act as a driver to the market growth.

Segmentation: Global Graft-Versus-Host Disease (GVHD) Market 

Graft-Versus-Host Disease (GVHD) Market : By Product Type

ATG therapies
IL2Rα (CD25) inhibitors
TNFα inhibitors
Other biologics
Calcineurin inhibitors
mTOR inhibitors
SOT therapies
Anti-neoplastic therapies
Stem Cell Treatments
Extracorporeal Photophoresis

Graft-Versus-Host Disease (GVHD) Market : By Treatment Type

Prophylaxis GVHD
Chronic GVHD
Acute GVHD

Graft-Versus-Host Disease (GVHD) Market : By End- Users

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Graft-Versus-Host Disease (GVHD) Market : By Geography

North America
South America
Middle East & Africa

Key Developments in the Graft-Versus-Host Disease (GVHD) Market :

On 13th January 2017, Kalytera Therapeutics, Inc. announced that it acquired Talent Biotechs Ltd.which is an Israel based company evaluating the use of CBD to prevent and treat Graft versus Host Disease (“GvHD”). This agreement will strengthen Kalytera’s position as an emerging market leader in cannabidiol (“CBD”) pharmaceuticals.

On 9th November, 2017, Merck received FDA Approval of PREVYMIS™ (letermovir) for prevention of Cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients. This drug will attract GVHD patients.

On 2nd August, 2017, The U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy. Being the first and only drug for the treatment of cGVHD in adults, it is leading the GVHD market currently.

Graft-Versus-Host Disease (GVHD) Market Drivers :

Large unmet needs for the management of GVHD.

High investment in the R&D is expected to drive the growth of the market.

Advancements in the diagnostic measures of the disease.

Graft-Versus-Host Disease (GVHD) Market Restraints :

Lack of regulatory guidelines and treatment regimens for this rare disease will restrain the growth of the market.

Lack of awareness in the population is expected to hamper the growth of the market.

Reasons to Purchase this Report:

Current and future of global graft-versus-host disease market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

Regions/Countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at country level

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @

Contact Us
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.

Read original article here.